Acticor Biotech SA
PAR:ALACT
Operating Margin
Acticor Biotech SA
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
FR |
A
|
Acticor Biotech SA
PAR:ALACT
|
3.9m EUR | N/A | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
327.3B USD |
30%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
155.6B USD |
25%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
135.1B USD |
38%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.3B USD |
38%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
116.3B AUD |
26%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.2B USD |
29%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.4B USD |
-5%
|
Acticor Biotech SA
Glance View
Acticor Biotech SAS engages in the research and development of an antithrombotic agent for the treatment of the acute thrombotic diseases. The company is headquartered in Paris, Ile-De-France and currently employs 22 full-time employees. The company went IPO on 2021-11-01. The firm is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Acticor Biotech SA's most recent financial statements, the company has Operating Margin of 0%.